Therapy News and Research

RSS

Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System

Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced positive clinical data from the company's recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation.

24 Sep 2018

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.

24 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Genes predicting person's height may provide clues about causes of varicose veins

A person's height and certain genes that predict height are associated with varicose veins and may provide clues about what causes this condition and ways to prevent and treat it, according to new research in the American Heart Association's journal Circulation.

24 Sep 2018

Functional Imagery Training helps lose five times more weight than talking therapy

Overweight people who used a new motivational intervention called Functional Imagery Training lost an average of five times more weight than those using talking therapy alone, shows new research published today by the University of Plymouth and Queensland University.

24 Sep 2018

New study finds height as possible risk factor for developing varicose veins

The taller you are, the more likely you are to develop varicose veins, according to a study led by Stanford University School of Medicine researchers that examined the genes of more than 400,000 people in search of clues to what causes this common but little understood condition.

24 Sep 2018

Researchers analyze response to combination immunotherapy for patients with rare skin cancer

Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

In proof-of-concept experiments, University of Alabama at Birmingham researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP.

24 Sep 2018

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis.

24 Sep 2018

Study: Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation

A multicenter clinical trial has found that a minimally invasive procedure called transcatheter mitral valve repair significantly reduced hospitalizations and mortality for heart failure patients with moderate-to-severe or severe functional mitral regurgitation.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch

In the largest multi-institutional study to date, led by researchers from Penn Medicine, the team found that among patients who underwent a transcatheter aortic valve replacement, a high number experienced severe and moderate cases of prosthesis-patient mismatch--meaning the implanted heart valve is too small for the patient which can lead to inadequate blood flow.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer

A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus-related head and neck cancer.

24 Sep 2018

New research suggests power of zebrafish as tool for cancer drug discovery

The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes.

24 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Scientist intends to fight pathogenic bacteria with viruses

Dr. Li Deng of Helmholtz Zentrum München has been awarded a Starting Grant of the European Research Council. The scientist intends to tackle antimicrobial resistance by fighting bacteria with their natural enemies - the viruses. The grant is endowed with nearly 1.5 million euros for five years.

21 Sep 2018

Study offers solid link between visceral organs and brain’s reward, motivation system

A novel gut-to-brain neural circuit establishes the vagus nerve as an essential component of the brain system that regulates reward and motivation, according to research conducted at the Icahn School of Medicine at Mount Sinai and published September 20 in the journal Cell.

21 Sep 2018

Therapy News and Research

Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Genes predicting person's height may provide clues about causes of varicose veins

Functional Imagery Training helps lose five times more weight than talking therapy

New study finds height as possible risk factor for developing varicose veins

Researchers analyze response to combination immunotherapy for patients with rare skin cancer

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

Study: Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer

New research suggests power of zebrafish as tool for cancer drug discovery

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

Scientist intends to fight pathogenic bacteria with viruses

Study offers solid link between visceral organs and brain’s reward, motivation system

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News